|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laplante M and Sabatini DM: mTOR signaling
at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choo AY, Yoon SO, Kim SG, Roux PP and
Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to
mediate cell-type-specific repression of mRNA translation. Proc
Natl Acad Sci USA. 105:17414–17419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guertin DA and Sabatini DM: The
pharmacology of mTOR inhibition. Sci Signal. 2:pe242009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang YJ, Duan Y and Zheng XF: Targeting
the mTOR kinase domain: The second generation of mTOR inhibitors.
Drug Discov Today. 16:325–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu K, Toral-Barza L, Shi C, Zhang WG,
Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al:
Biochemical, cellular, and in vivo activity of novel
ATP-competitive and selective inhibitors of the mammalian target of
rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaytseva YY, Valentino JD, Gulhati P and
Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ,
Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY: mTOR signaling pathway
is a target for the treatment of colorectal cancer. Ann Surg Oncol.
16:2617–2628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gulhati P, Cai Q, Li J, Liu J, Rychahou
PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T and Evers BM: Targeted
inhibition of mammalian target of rapamycin signaling inhibits
tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qian Y: Tumorigenic CancerStemCells,
Methods of Isolating and Using the Same. Google Patents,
US20110206735A1. 2011
|
|
14
|
Bedner E, Li X, Gorczyca W, Melamed MR and
Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry.
Cytometry. 35:181–195. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma XM and Blenis J: Molecular mechanisms
of mTOR-mediated translational control. Nat Rev Mol Cell Biol.
10:307–318. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang S, Bjornsti MA and Houghton PJ:
Rapamycins: Mechanism of action and cellular resistance. Cancer
Biol Ther. 2:222–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gossage L and Eisen T: Targeting multiple
kinase pathways: A change in paradigm. Clin Cancer Res.
16:1973–1978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alqurashi N, Hashimi SM and Wei MQ:
Chemical inhibitors and microRNAs (miRNA) targeting the mammalian
target of rapamycin (mTOR) pathway: Potential for novel anticancer
therapeutics. Int J Mol Sci. 14:3874–3900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dowling RJ, Topisirovic I, Alain T,
Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj
A, Liu Y, et al: mTORC1-mediated cell proliferation, but not cell
growth, controlled by the 4E-BPs. Science. 328:1172–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Serra V, Markman B, Scaltriti M, Eichhorn
PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S,
et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K
signaling and inhibits the growth of cancer cells with activating
PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roper J, Richardson MP, Wang WV, Richard
LG, Chen W, Coffee EM, Sinnamon MJ, Lee L, Chen PC, Bronson RT, et
al: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor
regression in a genetically engineered mouse model of PIK3CA
wild-type colorectal cancer. PLoS One. 6:e251322011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ilyas M, Tomlinson IP, Rowan A, Pignatelli
M and Bodmer WF: Beta-catenin mutations in cell lines established
from human colorectal cancers. Proc Natl Acad Sci USA.
94:10330–10334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Newton IP, Kenneth NS, Appleton PL, Näthke
I and Rocha S: Adenomatous polyposis coli and hypoxia-inducible
factor-1{alpha} have an antagonistic connection. Mol Biol Cell.
21:3630–3638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu W, Zhou W, Cheng M, Wang J, Liu Z, He
S, Luo X, Huang W, Chen T, Yan W and Xiao J: Hypoxia activates
Wnt/β-catenin signaling by regulating the expression of BCL9 in
human hepatocellular carcinoma. Sci Rep. 7:404462017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perry SW, Norman JP, Barbieri J, Brown EB
and Gelbard HA: Mitochondrial membrane potential probes and the
proton gradient: A practical usage guide. Biotechniques. 50:98–115.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brachmann SM, Hofmann I, Schnell C,
Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C and Maira SM:
Specific apoptosis induction by the dual PI3K/mTor inhibitor
NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Proc Natl Acad Sci USA. 106:22299–22304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cuda CM, Pope RM and Perlman H: The
inflammatory role of phagocyte apoptotic pathways in rheumatic
diseases. Nat Rev Rheumatol. 12:543–558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seitz C, Hugle M, Cristofanon S,
Tchoghandjian A and Fulda S: The dual PI3K/mTOR inhibitor
NVP-BEZ235 and chloroquine synergize to trigger apoptosis via
mitochondrial-lysosomal cross-talk. Int J Cancer. 132:2682–2693.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ducker GS, Atreya CE, Simko JP, Hom YK,
Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB,
et al: Incomplete inhibition of phosphorylation of 4E-BP1 as a
mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Oncogene. 33:1590–1600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thoreen CC, Kang SA, Chang JW, Liu Q,
Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem.
284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Yue P, Kim YA, Fu H, Khuri FR and
Sun SY: Enhancing mammalian target of rapamycin (mTOR)-targeted
cancer therapy by preventing mTOR/raptor inhibition-initiated,
mTOR/rictor-independent Akt activation. Cancer Res. 68:7409–7418.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu CX, Li Y, Yue P, Owonikoko TK,
Ramalingam SS, Khuri FR and Sun SY: The combination of RAD001 and
NVP-BEZ235 exerts synergistic anticancer activity against non-small
cell lung cancer in vitro and in vivo. PLoS One. 6:e208992011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blaser B, Waselle L, Dormond-Meuwly A,
Dufour M, Roulin D, Demartines N and Dormond O: Antitumor
activities of ATP-competitive inhibitors of mTOR in colon cancer
cells. BMC Cancer. 12:862012. View Article : Google Scholar : PubMed/NCBI
|
